Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals. • 612-624-2620 • 1-888-226-2376

Multiple Myeloma Clinical Trials

Protocol Number Title
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
MT2001-10 Allogeneic Bone Marrow Transplant Using Less Intensive Therapy
MT2003-13 Autologous Transplantation for Multiple Myeloma
MT2003-15 Use of Cyclophosphamide/Fludarabine to Promote in vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy after Allogeneic Transplant
MT2005-02 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
MT2005-10 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen
MT2006-01 Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+ CD4+ T-Regulatory (Treg) Cells After Non-Myeloablative Cord Blood Transplantation
MT2009-22R Monitoring of Immune Function and Minimal Residual Disease in Patients and Donors After Hematopoietic Cell Transplantation (HCT)
MT2010-12: A First-in Humans,single-center,open-label, proof-of concept-study to evaluate the safety and tolerability of infusing HSC835 (LFU835-expanded Umbilical Cord hematopoietic stem Cells In patients with hematological malignancies
HM2013-12 : IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
MT2012-24R Preparative Regimen Exposure-Response Relationships in Nonmyeloablative Stem Cell Transplants: Correlative Pharmacokinetics.
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (C16014)

13 trials displayed

  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on